We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: ID NOW Molecular Platform (Photo courtesy of Abbott)
Image: ID NOW Molecular Platform (Photo courtesy of Abbott)

Abbott (Lake Forest, IL, USA) participated in ECCMID 2022 where it highlighted its range of rapid diagnostic platforms that complement centralized RT-PCR testing as well as empowers labs to efficiently and cost-effectively extend their impact throughout hospitals.

Abbott’s product portfolio exhibited at ECCMID 2022 included ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The company’s ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing healthcare professionals to make effective clinical decisions sooner. Abbott demonstrated its Panbio COVID-19 Ag Rapid Test Device that can identify potentially contagious patients with or without symptoms in 15 minutes alongside its Panbio COVID-19 IgG/IgM Rapid Test Device for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood.

In addition, Abbott demonstrated its Afinion CRP rapid in vitro diagnostic test for the quantitative determination of C-reactive protein (CRP) in human blood in three minutes. Afinion CRP helps reduce diagnostic uncertainty and guides antibiotic decision-making during the patient’s visit. A significantly increased CRP result may indicate the need for immediate antibiotic treatment. CRP Point of care testing has been shown to reduce antibiotic prescribing by more than 60% if combined with communication training for general practitioners. The test runs on Abbott’s Afinion2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care. With the Afinion System, there’s no need to send patients to the lab or spend time tracking down their results.

Related Links:
Abbott 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.